Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Scherr, J. Anja, S. Salome, D. Miedinger, M. Sabrina, A. Taegtmeyer, C. Prashant, S. Anderson, T. Michael, J. D. Leuppi (Basel, Switzerland; Camperdown, Australia). Inhaled corticosteroids in patients with mild to moderate COPD with and without airway hyperresponsiveness to mannitol: A randomized placebo controlled trial. Eur Respir J 2011; 38: Suppl. 55, 3361

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: Results of a phase IIIb randomized controlled trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007 Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012 Randomized controlled trial of nebulized budesonide suspension in acute severe exacerbation of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002 Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma Source: Eur Respir J 2016; 47: 981-984 Year: 2016 The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial Source: Eur Respir J, 57 (6) 2003338; 10.1183/13993003.03338-2020 Year: 2021 Effects of inhaled corticosteroids on asthmatic inflammation: The FeNOtype trial Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Withdrawal of inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: who is suitable for a trial of withdrawal? Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo Source: Eur Respir J 2006; 28: Suppl. 50, 764s Year: 2006 Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007 The effect of salt room treatment on bronchial hyperresponsiveness in asthmatics: a randomised controlled trial Source: Eur Respir J 2005; 26: Suppl. 49, 505s Year: 2005 Severe asthma exacerbations with eosinophilic bronchitis: a randomized controlled comparison of the anti-inflammatory effects of deflazacort vs. prednisone Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Effects of regular formoterol treatment on airway hyperresponsiveness in patients with mild to moderate asthma Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003 Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial Source: Eur Respir J, 58 (1) 2100130; 10.1183/13993003.00130-2021 Year: 2021 Self-titration of inhaled corticosteroid and ß2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial Source: Eur Respir J, 56 (4) 2000170; 10.1183/13993003.00170-2020 Year: 2020 Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID Year: 2021 Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effects of combined therapy with nebulized b2-agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007